Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients

AIDS

Volumn 23, Issue 18, 2009, Pages 2537-2540

  Yilmaz, Aylin ^a   Watson, Victoria ^b,c   Else, Laura ^b   Gisslèn, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MARAVIROC; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG PENETRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; CYCLOHEXANES; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, CCR5; TRIAZOLES;

EID: 72949113630     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328333ae0e     Document Type: Article

References (13)

1. Mueller MC, Bogner JR. Treatment with CCR5 antagonists: which patient may have a benefit? Eur J Med Res 2007; 12: 441-452.
2. Thomas SA. Anti-HIV drug distribution to the central nervous system. Curr Pharm Des 2004; 10:1313-1324.
3. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dis-pos 2007; 35:1657-1663.
4. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38: 1330-1339.
5. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:203-209.
6. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12:1941-1955.
7. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol 1999; 73:205-213.
8. Li S, Juarez J, Alali M, Dwyer D, Collman R, Cunningham A, Naif HM. Persistent CCR5 utilization and enhanced macro-phage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol 1999; 73:9741-9755.
9. R cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-673.
10. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 2005; 191:890-898.
11. Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 2002; 25:537-562.
12. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neuro-tropism independent of coreceptor specificity. J Virol 2001; 75:10073-10089.
13. Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, et al. Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: evidence for a role of the envelope. J Virol 1999; 73:897-906.